TAFLOTAN-S OPHTHALMIC SOLUTION 0.0015%

国: シンガポール

言語: 英語

ソース: HSA (Health Sciences Authority)

有効成分:

Tafluprost

から入手可能:

SANTEN PHARMACEUTICAL ASIA PTE. LTD.

ATCコード:

S01EE05

医薬品形態:

SOLUTION, STERILE

構図:

Tafluprost 0.015mg

投与経路:

OPHTHALMIC

処方タイプ:

Prescription Only

製:

Santen Pharmaceutical Co Ltd (Noto Plant)

認証ステータス:

ACTIVE

承認日:

2015-09-23

製品の特徴

参天製薬　756731　MU_タフロタン点眼液(シンガポール)添付文書
2860-02〈06〉ｵﾓﾃ（21/09/03）
420×120　1° コン　　大光印刷株式会社
Composition
Taflotan ophthalmic solution 0.0015% is a clear, colorless, sterile
aqueous ophthalmic solution. Each
mL contains 15μg of tafluprost. It also contains Polysorbate 80,
concentrated glycerin, disodium
edetate hydrate, sodium dihydrogen phosphate dihydrate, benzalkonium
chloride and pH adjuster
(sodium hydroxide, hydrochloric acid) as additives. Its pH is 5.7 -
6.3 and its osmolar ratio is 1.0 - 1.1.
Indications
Reduction of intraocular pressure in patients with primary open-angle
glaucoma or ocular
hypertension.
Dosage and Administration
Instill 1 drop in the affected eye(s) once daily.

Do not use more than once daily because more frequent administration
may lessen the IOP-lowering
effect.
Pharmacology
1.Intraocular pressure (IOP) lowering effect
Ocular administration of tafluprost ophthalmic solutions ranged from
0.00002% to 0.005% in a
single dose to monkeys showed the IOP lowering effect in a
concentration-dependent manner.
The effect was statistically significant in the groups of the
concentration of 0.0005% and higher,
compared with the vehicle group. In a repeated dose study in monkeys
of tafluprost ophthalmic
solutions ranged from 0.001% to 0.005% once daily for 5 days, IOP
lowering effect at every
concentration was stable and did not attenuate during the
administration period.
2.Mechanism of action
Tafluprost acid form, an active metabolite, showed high affinity for
the prostanoid FP receptor
(Ki=0.40 nM). Aqueous humor dynamics in monkeys was evaluated using
fluorophotometry,
two-level constant pressure perfusion and
125
I-
131
I labelled albumin perfusion methods following
the repeated administration of 0.005% tafluprost ophthalmic solution
once daily for 3 to 5 days.
Uveoscleral outflow significantly increased without any change in
aqueous production.
3.Effect on ocular blood flow
(1)
A repeated installati